SCHEMBL3326075

SCHEMBL3326075

CC(C)(C)OC(=O)N1CCC[C@H](CS(C)(=O)=O)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPT P10636 1/20 0.51
KMT2A Q03164 1/20 0.51
SCN9A Q15858 1/20 0.50
KAT7 O95251 2/20 0.48
KAT8 Q9H7Z6 1/20 0.48
BACE1 P56817 2/20 0.47
CTSD P07339 1/20 0.47
GLS O94925 2/20 0.47
HPGD P15428 1/20 0.46
ACKR3 P25106 1/20 0.45
HTR6 P50406 3/20 0.44
BCHE P06276 2/20 0.44
NR1H2 P55055 1/20 0.43
KDM1A O60341 1/20 0.43
FEN1 P39748 1/20 0.43
GPR119 Q8TDV5 1/20 0.42
KAT6A Q92794 2/20 0.42
KAT5 Q92993 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31168740 1.00 MEN1 (0.51) MEN1ALDH1A1MAPTKMT2ASCN9A
SCHEMBL18088048 1.00 MEN1 (0.51) MEN1ALDH1A1MAPTKMT2ASCN9A
SCHEMBL31609153 0.92 GPR119 (0.49) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL20690682 0.92 GPR119 (0.49) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL31609166 0.92 GPR119 (0.49) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL21193024 0.89 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2ASCN9A
SCHEMBL9974300 0.88 MEN1 (0.56) MEN1ALDH1A1MAPTKMT2ASCN9A
SCHEMBL13059809 0.88 MEN1 (0.56) MEN1ALDH1A1MAPTKMT2ASCN9A
SCHEMBL13059808 0.88 MEN1 (0.56) MEN1ALDH1A1MAPTKMT2ASCN9A
SCHEMBL25699929 0.88 MEN1 (0.50) MEN1ALDH1A1MAPTKMT2ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114605327-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-03-11 CN disclosed
CN-114716381-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-03-11 CN disclosed
CN-114573510-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-02-25 CN disclosed
CN-114591242-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-01-07 CN disclosed
CN-114634447-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-11-15 CN disclosed
CN-113603645-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-10-29 CN disclosed
CN-113636978-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-10-29 CN disclosed
US-20100120858-A1 Piperidine Derivatives PFIZER INC. 2010-05-13 US disclosed
EP-2066630-A1 PIPERIDINE DERIVATIVES Pfizer Products Incorporated (US) 2009-06-10 EP disclosed
WO-2008023258-A1 PIPERIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120858-A1 Piperidine Derivatives P2RX5, P2RX7, P2RX1 MEN1 2104/4885ALDH1A1 128/4885MAPT 3998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.